| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 53.179 | 155.591 | 0 | 36.284 | 49.935 | 62.984 | 75.407 | 60.377 | 32.863 | 42.421 |
| Total Income - EUR | 53.776 | 157.099 | 4.817 | 48.641 | 53.067 | 65.330 | 77.472 | 61.457 | 32.923 | 43.120 |
| Total Expenses - EUR | 36.924 | 91.777 | 859 | 48.933 | 30.214 | 50.309 | 70.732 | 92.452 | 32.228 | 62.279 |
| Gross Profit/Loss - EUR | 16.852 | 65.322 | 3.958 | -293 | 22.853 | 15.021 | 6.740 | -30.995 | 695 | -19.160 |
| Net Profit/Loss - EUR | 14.089 | 57.075 | 3.454 | -1.752 | 21.269 | 13.212 | 5.612 | -31.597 | 373 | -19.582 |
| Employees | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 1 | 1 | 2 |
Check the financial reports for the company - Romedor Pharma Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 0 | 99.730 | 96.311 | 86.549 | 61.102 | 65.668 | 55.455 | 7.420 | 7.398 | 7.356 |
| Current Assets | 60.832 | 51.089 | 50.004 | 42.969 | 52.604 | 54.998 | 62.341 | 46.948 | 64.465 | 32.154 |
| Inventories | 6.311 | 5.617 | 5.522 | 6.062 | 22.671 | 20.916 | 13.819 | 2.601 | 14.997 | 25.032 |
| Receivables | 47.676 | 45.402 | 44.452 | 35.986 | 29.495 | 33.656 | 48.437 | 44.285 | 43.165 | 6.185 |
| Cash | 6.845 | 70 | 29 | 922 | 438 | 426 | 85 | 62 | 6.302 | 936 |
| Shareholders Funds | 52.703 | 109.240 | 110.847 | 81.552 | 66.289 | 78.244 | 82.122 | 21.456 | 21.764 | 2.060 |
| Social Capital | 45 | 45 | 44 | 43 | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | 8.130 | 41.579 | 35.468 | 47.966 | 47.417 | 42.421 | 35.674 | 32.912 | 50.099 | 37.450 |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "4646 - 4646" | |||||||||
| CAEN Financial Year |
4646
|
|||||||||
Comments - Romedor Pharma Srl